Regulatory Considerations for Biosimilars Development in the U.S.
The development of biosimilar products in the US has been progressing since the regulatory pathway was established as part of the Affordable Care Act. Listen as members of Veristat’s Regulatory team delve into the analytical and clinical science of biosimilars and their regulatory pathway.
downloadExplore Our Key Related Services
Please fill out this form to access your resource.